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Abstract 
The rapid ability of SARS-CoV-2 to spread among humans, along with the clinical complications of coronavirus disease 
2019—COVID-19, have represented a significant challenge to the health management systems worldwide. The 
acute inflammation and coagulation abnormalities appear as the main causes for thousands of deaths worldwide. 
The intense inflammatory response could be involved with the formation of thrombi. For instance, the presence of 
uncleaved large multimers of von Willebrand (vWF), due to low ADAMTS13 activity in plasma could be explained by 
the inhibitory action of pro-inflammatory molecules such as IL-1β and C reactive protein. In addition, the damage to 
endothelial cells after viral infection and/or activation of endothelium by pro-inflammatory cytokines, such as IL-1β, 
IL-6, IFN-γ, IL-8, and TNF-α induces platelets and monocyte aggregation in the vascular wall and expression of tissue 
factor (TF). The TF expression may culminate in the formation of thrombi, and activation of cascade by the extrinsic 
pathway by association with factor VII. In this scenario, the phosphatidylserine—PtdSer exposure on the outer leaflet 
of the cell membrane as consequence of viral infection emerges as another possible underlying mechanism to acute 
immune inflammatory response and activation of coagulation cascade. The PtdSer exposure may be an important 
mechanism related to ADAM17—mediated ACE2, TNF-α, EGFR and IL-6R shedding, and the activation of TF on the 
surface of infected endothelial cells. In this review, we address the underlying mechanisms involved in the pathophys-
iology of inflammation and coagulation abnormalities. Moreover, we introduce key biochemical and pathophysiologi-
cal concepts that support the possible participation of PtdSer exposure on the outer side of the SARS-CoV-2 infected 
cells membrane, in the pathophysiology of COVID-19.
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Background
Coronavirus disease 19 (COVID-19) has already caused 
hundreds of thousands of deaths and has become one 
of the humanity’s greatest health challenge in our time 
[1]. The acute inflammation and disseminated intravas-
cular coagulation appear as the main causes of mortal-
ity worldwide [2–4]. Efforts to overcome this challenge 
have been limited by worldwide hospital capacity and a 
lack of knowledge about crucial aspects of the infection 
and effective treatment options. Faced with this, sev-
eral therapeutic options have been studied and tested 
in order to find new strategies to limit/block viral entry 
and improve the main clinical complications related 
to the disease. Moreover, clinical interventions have 
emerged and brought important advances, such as reduc-
ing mortality and improving the prognosis of critically ill 
patients treated with anticoagulant/anti-inflammatory 
drugs [5]. However, the molecular bases underlying the 
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In this context, the phosphatidylserine—PtdSer expo-
sure on the outer leaflet of the membrane emerges as a 
possible underlying phenomenon in the pathophysiol-
ogy of COVID-19. Under physiological conditions, the 
PtdSer exposure on the outer leaflet of activated platelets 
provides a platform for the aggregation of various coag-
ulation factors [6], is involved with red cell senescence, 
cell activation and/or death [7–10] and with inhibition of 
activation of inflammatory and autoimmune mechanisms 
[11, 12]. However, in pathophysiological conditions, the 
PtdSer exposure may have deleterious effect relate to 
coagulation activation [13] and with viral infections [14–
16], increasing the infectivity and viral spread [17–21].
In this work, we introduce key biochemical and patho-
physiological evidences regarding the main mechanisms 
involved in the genesis of coagulation abnormalities and, 
in particular, the involvement of endothelial cells damage 
and/or activation-mediated by virus infection and acute 
inflammatory response. In this scenario, we also dis-
cussed the possible participation of phosphatidylserine-
PtdSer exposure on the outer leaflet of the membrane 
of SARS-CoV-2 infected cells as a possible underlying 
mechanism to acute immune inflammatory response and 
activation of coagulation cascade.
SARS‑CoV‑2 infection and the renin‑angiotensin 
system—RAS
The SARS-CoV-2 virus uses the surface spike (S) proteins 
for host cell attachment and infection. The precursor of S 
viral glycoprotein is cleaved into S1 and S2 polypeptides by 
furin, a host cell protease, in a polybasic site, RRAR^S, at 
the S1–S2 junction, which is absent in the SARS-CoV. This 
difference may be responsible for a more efficient cleavage 
of SARS-CoV-2 protein S, than that of the SARS-CoV, and, 
thus, explain the higher SARS-CoV-2 infectivity [22–24]. 
In addition, the polybasic sequence motif, RRAR, at C-ter-
minal sequence of the S1, termed the ’C-end rule’ (CendR) 
[22–24], can bind to the cell surface Neuropilin receptors 
(NRP1 and 2) [25–27]. The S1 and S2 proteins remain 
noncovalently linked and, after binding of SARS-S to the 
angiotensin-converting enzyme 2 (ACE2), the S2 protein 
is subsequently cleaved by a type II transmembrane serine 
protease (TTSP), TMPRSS2 [28]. Alternatively, another 
less important route of infection involves cathepsin L, a 
pH-dependent endo-lysosomal host cell protease, after the 
uptake of virions into target cell endosomes [29].
ACE2 is a negative regulator of the renin-angiotensin 
system (RAS), converting angiotensin (Ang) I and Ang II 
into Ang 1–9 and Ang 1–7, respectively [30] and, thus, 
protecting the cardiovascular system against systemic 
hypertension, myocardial infarction and diabetic cardio-
vascular complications [31, 32]. As a consequence of viral 
infection, ACE2 is internalized along with viral particles 
into endosomes, decreasing tissue ACE2 expression [33, 
34]. Among the main consequences of RAS imbalance 
are those related to vasoconstriction, hypertrophy, fibro-
sis and acceleration the thrombin generation pathway, 
as well as inflammation in COVID-19 patients [35, 36]. 
ACE2 downmodulation is intensified by the cleavage of 
cellular proteases, the disintegrin and metalloproteinase 
domain 17 (ADAM-17) and TMPRSS2, which enhance 
the imbalance in the RAS and leads to increased Ang 
II plasma levels in COVID-19 patients [37, 38]. The 
TMPRSS2-mediated ACE2 cytoplasmic tail cleavage may 
lead to an increase in viral uptake through the cathep-
sin L-dependent pathway [38]. Interestingly, the ACE2 
cytoplasmic tail, as well as ADAM17 expression have 
been found to be necessary to viral infection; however, 
the underlying mechanism by which ACE2 tail-mediated 
ADAM17 activation facilitates viral entry is still unclear. 
In particular, the internalization of ACE2 would trigger a 
harmful positive feedback pathway, since the decrease in 
ACE2 expression results in an increase in Ang II, which 
in turn leads to an excessive activation of AT1Rs, increas-
ing ADAM17 activity and the shedding of ACE2, and, 
thus depleting the tissue of ACE2 even more [39, 40]. 
Moreover, the up-regulation of ADAM17 activity may be 
triggered by increasing of IL-β levels, a pro-inflammatory 
cytokine induced by SARS-CoV-2 infection [41] (Fig. 1c). 
Finally, the increased ADAM-17 catalytic activity to 
remove the membrane proteins ectodomains (sheddase 
activity) also leads to the cleavage of TNF-α and interleu-
kin-6 receptor (IL-6R), as well as other pro-inflammatory 
molecules, reinforcing the inflammatory process [31, 42].
Several findings support the pathophysiological relevance 
of increased ADAM17-mediated ACE2 tissue degrada-
tion in both COVID-19’s comorbidities and SARS-CoV-2 
infection: (1) increased plasma levels of ACE2 soluble form 
(sACE2) with age in men [43, 44]; (2) higher expression 
levels of sACE2 in men with heart failure than woman, as 
consequence of increased ADAM17 activity [45]; and (3) 
higher ACE2 level expression and up-regulated activity of 
ADAM17 in patients with chronic pulmonary inflamma-
tion [46], chronic obstructive pulmonary disease (COPD) 
[43, 47], diabetes [48, 49] and renal diseases [50].
The relevance of increased ADAM17-mediated ACE2 
tissue degradation on cardiovascular diseases has been 
highlighted by Sama et  al. [45]. In that study, conducted 
in patients with heart failure, the ACE2 plasma levels were 
higher in men than in women with heart disease. The 
higher plasma levels of ACE2 have been interpreted as a 
consequence of higher ADAM17 activity, and as molecu-
lar marker of a poor prognosis [40]. In support of that 
interpretation, elevated levels of TNFα have been found 
in heart diseases such as myocarditis and correlated nega-
tively with left ventricular systolic function in patients [51].
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Pathophysology of COVID‑19
Acute respiratory distress syndrome
COVID-19 is associated with a high transmissibility 
rate when compared to other SARS-CoV diseases [52]. 
Symptomatic patients may have mild to severe clini-
cal respiratory manifestations, or very severe sequelae 
such as those resulting from acute respiratory distress 
syndrome (ARDS). The progression of some patients 
to ARDS may be related to a genetic susceptibility that 
promotes an imbalance between pro-inflammatory and 
anti-inflammatory mediators [2], leading to an exac-
erbated immune-inflammatory response. This clinical 
Fig. 1 Molecular mechanisms involved in the acute inflammation and coagulation abnormalities of COVID-19. a The SARS-CoV-2 infection triggers 
an inflammatory cellular infiltrate in the alveolar lumen releases toxic molecules by macrophages and neutrophils, such as IL-1β, IL-8, IL-6 and 
TNF-α. The cytokines storm lead to diffuse alveolar damage, pulmonary oedema. b The damage and /or activation of blood vessels endothelium 
by viral infection and pro-inflammatory cytokines respectively induce platelet and monocyte aggregation in the vascular wall. These events are 
accompanied by increased expression of the tissue factor (TF) leading to activation of extrinsic pathway coagulation cascade culminating with the 
thrombi formation. Moreover, the thrombotic microangiopathy, may also be consequence of uncleaved large multimers of VWF, due to a decrease 
in the plasma levels of ADAMTS13. c Finally, as consequence of blood vessels endothelium viral infection, ACE2 is internalized, and sheddase 
activity of ADAM17 is increased. The ACE2 downmodulation and TNF-α and IL-6R release exacerbates the imbalance of RAS, leading to increase 
inflammation. The virus-mediated PtdSer exposure on the outer leaflet of the cell membrane emerge as an underlying mechanism to activate TF 
and extrinsic pathway coagulation cascade and inflammation (not shown)
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syndrome is characterized by the following features: the 
acute establishment of dyspnea that progresses to severe 
respiratory failure; a reduction in oxygen partial pres-
sure (hypoxemia); bilateral pulmonary infiltrates; and 
clinical absence of left heart failure. SARS-CoV-2 infec-
tion causes virus-related epithelial pyroptosis in type 
I and II pneumocytes and activation of macrophages in 
the pulmonary alveoli [53]. Activated macrophages are 
the main source of pro-inflammatory cytokines such 
as IL-1β, IL-6, IFN-γ, IL-8, and TNF-α [54, 55]. These 
cytokines activate the acute inflammatory response due 
to increased endothelial permeability and a chemotactic 
effect on neutrophils, monocytes, and cytotoxic T lym-
phocytes. These inflammatory cellular infiltrates in the 
alveolar lumen subsequently release toxic molecules, 
leading to diffuse alveolar damage, pulmonary edema, 
and fibrin deposition (hyaline membrane) into the alveo-
lar space [4] (Fig. 1a).
Inflammation and coagulation abnormalities
The unfavorable evolution of ARDS patients is connected 
with multiple organ failure, which in turn is strongly 
associated with coagulation abnormalities such as throm-
botic events; microvascular platelet-rich thrombotic dep-
osition in different organs [3, 4, 56] have been observed 
during early stages of COVID-19, while disseminated 
intravascular coagulation (DIC) has been observed in 
later stages [57]. The latest anatomopathological data 
are related to thrombotic microangiopathy. The pre-
disposition to the arterial and venous thrombi forma-
tion in patients with COVID-19 may be related to two 
main non-exclusive and related mechanisms: the intense 
inflammatory response and cell injury by virus infection.
The intense inflammatory response and thrombi for-
mation are interrelated via positive feedback [58]. In 
early stages of the inflammatory response, the throm-
botic phenomena could be facilitated by two different 
ways. The first may involve passage of inflammatory 
mediators to the circulation, such as the pro-inflamma-
tory cytokines TNF-α, IL-1β and IL-6, generated at the 
pulmonary tissue [54]. The activation of endothelium by 
these pro-inflammatory cytokines facilitate  platelet and 
monocyte aggregation, as well as the expression of a gly-
coprotein known as a tissue factor (TF) in the vascular 
wall. The increased expression of TF, both in endothelial 
cells and monocytes, may activate the coagulation cas-
cade culminating in the formation of thrombi [58–60] 
by binding to factor VII, forming the TF/FVIIa complex 
(Fig. 1c). A study conducted by Ethan et al. [61] analyz-
ing transcriptomic data sets of SARS-CoV-2 human 
infected bronchial epithelial cells found significantly 
increased F3 gene expression encoding TF protein [61]. 
These findings strongly suggest that hyper-activation of 
the extrinsic blood coagulation cascade in patients with 
COVID-19 may be a critical mechanism for the develop-
ment of coagulopathies. In addition, the increased IL-6 
levels were correlated with increased fibrinogen, linking 
inflammation to abnormalities of coagulation [62]. These 
phenomena might explain the laboratory data demon-
strating high levels of D-dimer, mild decrease platelet 
count, increase plasma fibrinogen levels, low levels of 
anti-thrombin, and prothrombin time extension (PT), as 
well as the clinical manifestations of DIC in later stages 
in patients with COVID-19 [63]. The other mechanism 
involves the IL-1β and C reactive protein-mediated large 
von Willebrand factor multimers (vWF) accumulation in 
plasma. This mechanism may be due to decreased activity 
of a disintegrin or metalloprotease with thrombospondin 
type 1 repeats 13—ADAMTS13. The ADMTS13 down-
modulation could be explained by the inhibitory effect of 
pro-inflammatory molecules such as IL-1β and C reac-
tive protein, as shown by Chen and colleagues in patients 
with lymphoblastic leukemia [64]. Indeed, several stud-
ies have shown that plasma of COVID-19 patients with 
microangiopathy contains low ADAMTS13 activity and 
increased vWF and factor VII levels [65, 66]. However, 
in a recent study conducted by Escher and colleagues, 
no role of ADAMTS13 in the pathogenesis of COVID-19 
coagulopathy was observed [67].
Regarding injury or endothelial cells dysfunction 
as a result of virus infection, three main pathophysi-
ological consequences are possible. One consequence 
is the aggregation of platelets, leading to an imbalance 
between pro- and anti-anticoagulant agents. In this 
sense, Zhang et al. [68] showed that SARS-CoV2 virus 
directly activates platelets through the spike/ACE2 
interactions, potentiating their prothrombotic func-
tion and inflammatory response. These events correlate 
with histopathological findings in pulmonary vessels of 
COVID-19 patients, such as the high incidence of alve-
olar capillary microthrombi, pulmonary thromboembo-
lism, and other vascular occlusive events (e.g. ischemic 
limbs, strokes) [69–71]. A second consequence is an 
increase in the level of vWF and infiltration of active 
neutrophils and macrophages (endothelialitis), and the 
formation of neuthrophil extracellular traps (NETs) [72, 
73]. The NETs can increase damage to the endothelium, 
and consequently activate both extrinsic and intrinsic 
pathways [74]; this could cause development of a pro-
thrombotic state that could be facilitated by hypoxia-
inducible factor (HIF) after lung injury [75]. One final 
possible consequence of viral infection is the internali-
zation of ACE2 receptor from the surface of epithelial 
cells in the pulmonary alveoli, AT1Rs activation [76], 
and ADAM-17 and TMPRSS2 cleavage. The ACE2 
downmodulation causes an imbalance of the RAS 
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system, leading to an increase in Ang II plasma levels 
and facilitating thrombosis via a thrombin-dependent 
pathway (Fig. 1b) [35].
PtdSer translocation and viral infections
PtdSer is one of the main acidic and the most abundant 
negatively charged phospholipids in mammalian cell 
membranes [77, 78]. PtdSer is asymmetrically distrib-
uted between the inner and outer leaflets of the lipid 
bilayer, and it is translocated in response to membrane 
perturbation, cell damage or intracellular signals [79]. 
Transient PtdSer exposure has been reported in condi-
tions such as PKC activation [80] and cytosolic  Ca2+ 
elevation [81], showing that diverse stimulus that can 
lead to exposure of PtdSer to the outer membrane leaf-
let. PtdSer translocation can be triggered basically by 
two mechanisms: elevated  Ca2+ ionophores or apoptosis 
[82]. Both processes are accompanied by the activation of 
“scramblases”, proteins that expose PtdSer by translocat-
ing phospholipids between the inner and outer leaflets 
of the plasma membrane to the cells surface [83]. Dur-
ing apoptosis, caspase-dependent Xkr8 (Xkr8) activation 
leads to irreversible “flippase” inactivation. In contrast, in 
response to cytoplasmic  Ca2+ elevation, the transmem-
brane 16F lipid-scramblase protein (TMEM16F/anoc-
tamin 6) is activated and translocates PtdSer to the outer 
side of the cell membrane [83]. In addition, TMEM16F 
can act as a regulator of  Ca2+ activated membrane traf-
fic [84] or promote plasma membrane repair after pore 
formation [85]. PtdSer exposure acts as a signal for dead 
cell phagocytosis by macrophages, avoiding the activa-
tion of inflammatory and autoimmune mechanisms [11, 
12]. Phagocytosis associated with PtdSer translocation 
could be an early event associated with viral infections, 
as described with influenza A virus [14], HIV-1 [15], and 
herpes simplex virus-1 [16]. Moreover, enveloped viruses 
like HIV-1, Ebola (EBOV), West Nile, Dengue and Zika 
viruses incorporate PtdSer to increase viral entry by 
binding to T-cell immunoglobulin (Ig) and mucin domain 
(TIM) proteins [17–21]. In a recent study, it was shown 
that HIV-1 activates TMEM16F “scramblase” to expose 
PtdSer on the outer leaflet of host cell membrane to 
increase viral infectivity [86]. Although this mechanism 
has not yet been addressed in coronavirus infection, Ptd-
Ser translocation by TMEM16F-scramblase activation 
cannot be ruled out and deserves further investigation.
PtdSer and pathophysiology of COVID‑19
PtdSer exposure in pathophysiological conditions
Exposure of PtdSer on the outside of the cell membrane 
also occurs under certain biological conditions such 
as platelet activation, microvesicle shedding from cell 
surfaces, anoxia, red cell senescence, and cell activa-
tion or death [7–10]. Coagulation plays a critical role in 
hemostasis and in the innate immune response to infec-
tion in an effort to avoid the dissemination of microbes 
[87]. However, under some pathological conditions, the 
activation of coagulation could be deleterious. Indeed, 
in a mouse endotoxemia and bacterial sepsis model, cas-
pase-11, a cytosolic lipopolysaccharide (LPS) receptor, 
enhanced the pro-coagulant activity of TF independ-
ent of cell death. The activation of caspase-11 increased 
calcium influx through the formation of gasdermin D 
(GSDMD) pores, which led to TMEM16F scramblase-
mediated PtdSer exposure [13]. In addition, the forma-
tion of GSDMD pores by  K+ efflux led to activation of the 
NOD-like receptor (NLR) family pyrin domain-contain-
ing 3 (NLP3) inflammasome and increases in the release 
of IL-1β. The IL-1β and IL-1α levels in septic patients 
were significantly correlated with the PtdSer exposure 
on the outer side of the leukocyte membrane and with 
the DIC score. Caspase 11 deletion significantly inhib-
ited LPS-induced thrombin and thrombin-antithrombin 
complex (TAT) generation, D-dimer, platelet aggrega-
tion, and plasminogen activator inhibitor type 1 (PAI-1) 
in plasma [13]. On the outer side of the membrane, Ptd-
Ser is able to positively modulate TF activation and ini-
tiate the coagulation cascade [88]. The transcriptional 
upregulation of TF in the NHBEs support the possibility 
of PtdSer-mediated TF activation in infected endothe-
lial cells [61]. Moreover, under physiological conditions, 
 Ca2+-mediated PtdSer exposure on the outer leaflet of 
activated platelets provides a platform for the aggrega-
tion of various coagulation factors [6]. In Scott syndrome, 
a bleeding disorder, the lack of procoagulant activ-
ity in activated platelets is related to a mutation in the 
TMEM16F “scramblase” protein [89].
PtdSer exposure and COVID‑19 inflammatory response
The molecular mechanisms by which ADAM17 is reg-
ulated have not yet been fully elucidated, but would 
depend on the stimulus and the cell type. For instance, 
the release of the soluble active TNFα form and of the 
epidermal growth factor receptor (EGFR) by ADAM17 
depends on iRhom2 protein, an inactive member of the 
rhomboid family, and would be essential for maturation 
and substrate specificity of ADAM17 [90]. The ADAM17 
activity can be induced by other molecular stimuli 
including PKC activators, purine 2 (P2) receptor agonists, 
fibroblast growth factor 7 (FGF7),  Ca2+ ionophores, and 
membrane perturbations [91, 92]. ADAM17 can also be 
activated in response to infection by pathogens through 
Toll-like receptor activation [93, 94]. PtdSer on the outer 
side of the cell membrane also plays an important role as 
a docking site for enzymes such as Src kinase and protein 
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kinase C (PKC), establishing protein-lipid interactions 
sustained by electrostatic forces between the negatively 
charged phospholipid head group and cationic amino 
acid clusters [77]. Indeed, the PtdSer translocation was 
described as important requirement for ADAM17 to 
exert its “sheddase” activity [82] (Fig. 2a). Elliott et al. [95] 
showed that rapid PtdSer translocation was correlated 
with release of the ADAM17 substrate L-selectin after 
stimulation with purinergic receptor (P2) receptor ago-
nists, independent of any apoptotic events. In this con-
text, Sommner et al. [82] propose a model of ADAM17 
membrane sheddase activity and PtdSer exposure. In this 
model, the interaction of PtdSer and ADAM17 brings the 
protease into position for substrate processing. A recent 
work has shown that exposure of PtdSer is required 
for activation of ADAM10 sheddase activity [96]. The 
same PtdSer cationic binding motif as that identified in 
ADAM17 has also been identified [82, 97]. However, as 
opposed to the ADAM17 shedadase activation mecha-
nism, Anoctamin-6, a  Ca2+-activated ion channel that 
also functions as a scramblase, would be responsible for 
shuttling PtdSer from the internal to the outer membrane 
leaflet and ADAM10 activation [96]. Taking into account 
that the ADAM17 sheddase activity can remove the 
membrane protein ectodomains, the PtdSer-mediated 
ADAM17 activity may be the underlying mechanism for 
the cleavage of ACE2, TNFα, IL6R, EGFR, and other pro-
inflammatory molecules; these are critical components in 
the inflammatory process during SARS-CoV-2 infection.
PtdSer exposure and COVD‑19 coagulopathy
The coagulation abnormalities observed in COVID-19 
patients may be linked to changes in the plasma home-
ostasis of membrane phospholipids. The extracellular 
PtdSer exposure could activate the body’s inflammatory 
and coagulation cascades. In support of this hypothesis, 
Fig. 2 Model of ADAM17 and extrinsic pathway of coagulation cascade activation by PtdSer externalization. a As a consequence of SARS-CoV-2 
infection, ACE2 is internalized, increasing the Ang II/AT1R-axis. Both stimuli, ACE2 down-modulation and the high Ang II level trigger intracellular 
signals that culminate in  Ca2+ influx, and TMEM16F-scramblase activation, leading to PtdSer externalization to the outer cell membrane. The 
interaction between the ADAM17 cationic conserved sequence domain with the negatively charged PtdSer head group on the outer leaf 
membrane, bring the protease in the right position for ACE2 processing, with detrimental effects. Additionally, the ADAM17 “shedasse” activity also 
release of proinflamatory cytokine TNF-α and IL-6R increasing inflammatory process. b Finally, the PdSer exposure on the outer membrane may 
also activate the extrinsic pathway of coagulation cascade by enhancing the activation of tissue factor, being able to contribute to disseminated 
intravascular coagulation—DIC observed in COVID-19 patients
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Zang et.al demonstrated the presence of antiphospho-
lipid antibodies targeting phospholipid proteins (Anti-
cardiolipin IgA, anti-β2 glycoprotein I IgA and IgG), 
characteristic of antiphospholipid syndrome (APS), in 
three patients with admitted to the ICU with COVID-
19 and coagulopathy [98]. Interestingly, Zigon et  al. 
[99] showed a strong correlation between the antipro-
trombin and PtdSer/Protrombin complex antibodies 
in patients with clinical manifestations of APS, such as 
arterial and venous thromboses and  obstetric  compli-
cations. These data raise the possibility of phospholipid 
involvement in the pathophysiology of coagulopathies 
in patients with COVID-19, and the use of these sero-
logical markers of severe coagulopathy in COVID-19 
patients. Alternatively, PtdSer translocation is related 
to elimination of senescent and damaged cells via bind-
ing to membrane receptors on macrophages, avoid-
ing spillage of cellular contents and inflammation 
[100, 101]. However, during sepsis or inflammatory 
events like SARS-CoV-2 infection, PtdSer exposure 
could be up-regulated on cell surfaces throughout the 
body, including endothelial cells, platelets, erythro-
cytes, neutrophils, lymphocytes, and extra cellular 
microparticles. The possible underlying mechanism of 
these events could be related to the super-activation of 
TMEM16F scramblase along with PtdSer exposure on 
the outer leaflet of cellular membrane. In the context 
of SARS-CoV-2 infection, the intracellular conditions 
required for TMEM16F scramblase activation, such as 
cytoplasmic  Ca2+ elevation, also necessary for PtdSer 
translocation, may be triggered by viral infection itself 
and ACE2 downmodulation/Ang II increase/AT1R axis 
activation. Finally, the PtdSer-mediated TF activation 
would lead to the formation of thrombi and activation 
of extrinsic pathway of coagulation by association with 
factor VII (Fig. 2b) [102, 103].
In summary, based on the main pathophysiological 
mechanisms involved in PtdSer exposure, it is plausi-
ble to think that PtdSer translocation to the outer leaf-
let of the plasma membrane of the infected alveolar and 
endothelial cells may be one of the underlying mecha-
nisms in the inflammation and coagulation abnormali-
ties of COVID-19.
Concluding remarks
SARS-CoV-2 strategies to enhance viral infectivity, 
along with COVID-19 clinical complications, such as 
severe acute inflammation and coagulation abnormali-
ties (DIC and the thrombi formation), have resulted 
in significant obstacles in the development of effective 
therapies in this pandemic. Therefore, understand-
ing the pathogenic mechanisms underlying the clinical 
manifestations of COVID-19 has become a priority in 
the development of new anti-COVID-19 approaches.
The occurrence of these comorbidities could be 
related to the following main mechanisms: (1) acti-
vation of endothelium cells by pro-inflammatory 
cytokines, known as the “cytokines storm"; (2) viral 
infection-mediated endothelial cells damage and 
extrinsic pathway activation, through inducing TF 
expression; (3) decrease plasma activity of ADAMTS 
13 metalloproteinase, with subsequent accumulation 
of vWF multimers in plasma and formation of platelet 
microaggregates in the circulation; (4) and RAS unbal-
ancing mediated Ang II high plasma levels following by 
thrombin activation (Fig. 1).
In this context, the exposure of PtdSer on the outer 
side of the cell membrane, in cells infected by SARS-
CoV-2, emerges as another possible mechanism 
involved in the genesis of coagulation cascade acti-
vation by inducing TF activity. Moreover, the PtdSer 
exposure on the outer lipid bilayer may contribute to 
acute inflammation by increasing the sheddase activ-
ity of ADAM17, and, consequently, the ACE2, TNF-α, 
EGFR and IL-6R release, along with other inflamma-
tory molecules leading to acute inflammation (Fig. 2a). 
Thus, the pathophysiological concepts introduced in 
this review support the possible participation of PtdSer 
exposure on the outer side of the SARS-CoV-2 infected 
cells membrane in the pathophysiology of Covid-19, 
and open a new avenue of research in the identification 
of new therapeutic targets against COVID-19.
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charide; TAT : Thrombin-antithrombin complex; TMEM16F/anoctamin 6: Trans-
membrane 16F lipid-scramblase protein; FGF7: Fibroblast growth factor 7.
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